Oxford Pharmascience’s interim results provide an update on the group’s development activities. The group continues to be focused on the progression of OXPzero™ Ibuprofen and OXPzero™ Naproxen and is preparing to request a meeting with the FDA to clarify the regulatory pathway. Commercialisation discussions in respect of OXPzero™’s taste-masking benefit are ongoing and an update will be provided in due course. NSAIDs represent one of the most widely used drug classes in the world, but their use ....
